Skip to main content
Clinical Trials/NCT01818375
NCT01818375
Completed
Not Applicable

Goal-directed Fluid Therapy and Postoperative Ileus After Elective Laparoscopic Colorectal Surgery Using an Enhanced Recovery Program: a Randomized Controlled Trial

Gabriele Baldini, MD, MSc, Assistant Professor1 site in 1 country128 target enrollmentFebruary 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postoperative Ileus
Sponsor
Gabriele Baldini, MD, MSc, Assistant Professor
Enrollment
128
Locations
1
Primary Endpoint
Primary postoperative ileus (POI)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Despite Goal Directed Fluid Therapy (GDFT) has shown a reduction of hospitalization and overall complications in patients undergoing abdominal surgery, there is a need to address the effect of implementing GDFT on the incidence of specific surgical complications and in a context of en enhanced recovery program (ERP). Specifically, studies investigating the impact of GDFT on primary postoperative ileus (POI) in patients undergoing laparoscopic colorectal surgery and using an ERP are missing.

It is hypothesized that the incidence of primary POI will be reduced in patients receiving intraoperative GDFT compared to patients receiving Standard Fluid Therapy (SFT) after elective laparoscopic colorectal surgeries with an ERP program.

Detailed Description

Randomized Controlled Trial. Study population: elective laparoscopic colorectal resections with an Enhanced Recovery Program (ERP) Sample size: 128 patients (140 accounting for drops out) Two arms: GDFT: patients will receive GDFT esophageal doppler guided; SFT: patients will receive SFT based on standard anesthesia formula and international guidelines to calculate fluid requirements. Study Hypothesis: the incidence of primary POI will be reduced in patients receiving intraoperative GDFT compared to patients receiving SFT after elective laparoscopic colorectal surgeries with an ERP program. ERP: all patients will receive the same perioperative care according to the Enhanced Recovery After Surgery ERAS® program guidelines. Intravenous fluid will be stopped the first day after surgery. Patients will be allowed to have clear fluids the same day of surgery and diet, as tolerated, the first day after surgery.

Registry
clinicaltrials.gov
Start Date
February 2013
End Date
August 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Gabriele Baldini, MD, MSc, Assistant Professor
Responsible Party
Sponsor Investigator
Principal Investigator

Gabriele Baldini, MD, MSc, Assistant Professor

MD, MSc, Anesthesiologist, Assistant Professor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria

Inclusion Criteria

  • All patients undergoing elective laparoscopic colorectal resection with an Enhanced Recovery Program

Exclusion Criteria

  • Age \<18 yr
  • Emergency surgery
  • Patients who do not understand, read or communicate in either French or English
  • Patients who had undergone esophageal or gastric surgery
  • Esophageal pathology (esophageal varices or cancer)
  • Patients with coarctation of the aorta or aortic stenosis
  • Chronic atrial fibrillation
  • Preoperative bowel obstruction
  • Coagulopathies
  • Chronic use of opioids

Outcomes

Primary Outcomes

Primary postoperative ileus (POI)

Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days

Patients will be considered having primary POI if at least one symptom, for each of the following criteria, will be reported: i. vomiting (+/- nausea) OR abdominal distension AND ii. Absence of passing gas/stool OR not tolerating oral diet.

Secondary Outcomes

  • Intraoperative hemodynamic measurements(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Intraoperative and postoperative fluids and blood products required(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Vasoactive agents required(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Urinary output(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Intraoperative and postoperative urinary output(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Intraoperative and Postoperative opioid consumption(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Postoperative nausea and vomiting (PONV)(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Time spent out of bed(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Postoperative complications (Clavien Classification)(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Patients' weight(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Quality of surgical recovery score(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Readiness to be discharged(Participants will be followed for the duration of hospital stay, an expected average of 3 days)
  • Length of hospital stay(Participants will be followed for the duration of hospital stay, an expected average of 3 days)

Study Sites (1)

Loading locations...

Similar Trials